Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cutia Therapeutics ( (HK:2487) ) has issued an announcement.
Cutia Therapeutics announced the establishment of a Nomination Committee as part of its corporate governance structure. This committee, formed by the board of directors, aims to ensure diversity and independence in its membership, which may enhance the company’s decision-making processes and strengthen its governance framework.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on developing and providing therapeutic solutions, with its operations and stock listed on The Stock Exchange of Hong Kong Limited.
Average Trading Volume: 1,252,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.14B
For an in-depth examination of 2487 stock, go to TipRanks’ Overview page.